Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Zenagamtide s.c. phase 2 (T2D)

Zenagamtide s.c. phase 2 (T2D)

Amycretin · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Amycretin
Population
t2d
Phase
2
Participants
38
Duration
36 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
zenagamtide 10 mg weeklyt2d3638−12.9 % vs −2.1 %
Δ −10.8 pp
—−1.4 vs −0.121.0 vs 6.0—26.0 vs 14.011.0 vs 6.013.0 vs 8.0−9.4 vs −3.5verified
zenagamtide 20 mg weeklyt2d3638−13.1 % vs −2.1 %
Δ −11.0 pp
—−1.6 vs −0.134.0 vs 6.045.0 vs 14.050.0 vs 14.024.0 vs 6.08.0 vs 8.0−7.2 vs −3.5verified
zenagamtide 40 mg weeklyt2d3638−14.6 % vs −2.1 %
Δ −12.5 pp
—−1.7 vs −0.134.0 vs 6.045.0 vs 14.037.0 vs 14.029.0 vs 6.03.0 vs 8.0−10.6 vs −3.5verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (23)
  • zenagamtide 10 mg weekly · weight_eff · Table 2, Bodyweight change, % row
    −4·3 −7·6 −8·2 −12·9 −13·1 −14·6 −2·1
  • zenagamtide 10 mg weekly · ae_dc · Table 3
    Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
  • zenagamtide 10 mg weekly · nausea · Table 3
    Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
  • zenagamtide 10 mg weekly · vomiting · Table 3
    Vomiting 1 (3%) 1 (3%) 6 (16%) 4 (11%) 9 (24%) 11 (29%) 2 (6%)
  • zenagamtide 10 mg weekly · sae · Results, adverse events paragraph; Table 3
    five (13%) in the 10 mg group
  • zenagamtide 10 mg weekly · hba1c · Table 2
    Change from baseline at week 36 −0·9 −1·3 −1·0 −1·4 −1·6 −1·7 −0·1
  • zenagamtide 10 mg weekly · sbp · Table 2, SBP row
    Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5
  • zenagamtide 20 mg weekly · weight_eff · Table 2, Bodyweight change, % row
    −4·3 −7·6 −8·2 −12·9 −13·1 −14·6 −2·1
  • zenagamtide 20 mg weekly · ae_dc · Table 3
    Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
  • zenagamtide 20 mg weekly · disc_any · Results, paragraph 2
    17 (45%) of 38 participants in the zenagamtide 20 mg and 40 mg groups
  • zenagamtide 20 mg weekly · nausea · Table 3
    Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
  • zenagamtide 20 mg weekly · vomiting · Table 3
    Vomiting 1 (3%) 1 (3%) 6 (16%) 4 (11%) 9 (24%) 11 (29%) 2 (6%)
  • zenagamtide 20 mg weekly · sae · Results, adverse events paragraph; Table 3
    three (8%) in the 20 mg group
  • zenagamtide 20 mg weekly · hba1c · Table 2
    Change from baseline at week 36 −0·9 −1·3 −1·0 −1·4 −1·6 −1·7 −0·1
  • zenagamtide 20 mg weekly · sbp · Table 2, SBP row
    Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5
  • zenagamtide 40 mg weekly · weight_eff · Results, paragraph 7; Table 2
    to −14·6% with zenagamtide 40 mg (−12·5% [−16·79 to −8·21]; p<0·0001), compared with −2·1% with placebo
  • zenagamtide 40 mg weekly · ae_dc · Table 3
    Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
  • zenagamtide 40 mg weekly · disc_any · Results, paragraph 2
    17 (45%) of 38 participants in the zenagamtide 20 mg and 40 mg groups
  • zenagamtide 40 mg weekly · nausea · Table 3
    Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
  • zenagamtide 40 mg weekly · vomiting · Results, adverse events paragraph; Table 3
    vomiting in one (3%) of 38 participants in the 0·4 mg group and 11 (29%) of 38 participants in the 40 mg group
  • zenagamtide 40 mg weekly · sae · Results, adverse events paragraph; Table 3
    one (3%) in the 40 mg group
  • zenagamtide 40 mg weekly · hba1c · Results, paragraph 3; Table 2
    to −1·7% with zenagamtide 40 mg (−1·56% [−2·05 to −1·07]; p<0·0001; table 2)
  • zenagamtide 40 mg weekly · sbp · Table 2, SBP row
    Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Zenagamtide s.c. phase 2 (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/zenagamtide-s-c-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.